贝伐珠单抗治疗晚期子宫内膜癌的真实世界回顾性研究
这项单中心回顾性研究纳入101例组织学确诊的晚期/复发性子宫内膜癌患者,2004–2017年接受贝伐珠单抗单药治疗。主要终点为RECIST v1.1疗效,无完全或部分缓解,19例疾病稳定,临床获益率19%(95%CI 12–28%),中位总生存3.4年。结论认为在重度经治患者中疗效有限,仍可作为姑息选择。
要点
- 贝伐珠单抗单药在重度经治晚期子宫内膜癌中无CR/PR,临床获益率19%。
- 临床获益率随既往治疗线数增加而升高:1线7%、2线17%、3线21%、≥4线23%。
- 中位总生存3.4年,3年总生存率58%,最常见不良事件为高血压。
核心结论
- 在重度经治的晚期子宫内膜癌中,贝伐珠单抗单药临床疗效有限,但仍可作为姑息治疗选择。
研究设计与样本
- 单中心回顾性研究,纳入2004–2017年在该机构接受贝伐珠单抗治疗的组织学确诊子宫内膜癌患者101例。
- 主要终点为根据RECIST v1.1评估的治疗反应。
主要发现
- 无患者达到完全缓解或部分缓解,19例达到疾病稳定。
- 临床获益率(CR+PR+SD)为19%(95%CI:12–28%)。
- 既往治疗1、2、3、≥4线的临床获益率分别为7%、17%、21%、23%。
- 中位无进展生存期从2.6个月(2线)至4.9个月(≥4线)。
- 3年总生存率为58%(95%CI:47–67%),中位总生存3.4年(95%CI:2.9–4.2),范围从2.5年(2线)至4.5年(≥4线)。
临床怎么用
- 对于重度经治的晚期/复发性子宫内膜癌,贝伐珠单抗单药可作为姑息治疗选项,但需告知患者临床获益率有限。
- 治疗期间应监测高血压等不良事件,多数为1–2级。
局限性
- 本研究为单中心回顾性研究,样本量有限(n=101)。
- 贝伐珠单抗为超说明书使用,缺乏前瞻性对照数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prospective data have demonstrated the efficacy of bevacizumab monotherapy in the treatment of advanced endometrial cancer. Bevacizumab is used off-label, and real-world data regarding the role of bevacizumab in endometrial cancer treatment are scant. In this largest single-institution retrospective study of its kind, we report our experience with bevacizumab monotherapy in the treatment of advanced/recurrent endometrial cancer. METHODS: All eligible patients (n = 101) had histologically confirmed endometrial cancer and were treated with bevacizumab at our institution from 2004 to 2017. Demographic data and tumor characteristics were obtained through chart review. Primary objective was response to therapy determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). RESULTS: Analysis included 13 grade 1/2 endometrioid, 15 grade 3 endometrioid, 44 serous, 8 carcinosarcoma, and 21 other/mixed histologies. No patients achieved complete (CR) or partial (PR) responses; 19 achieved stable disease (SD). The clinical benefit rate (CBR; CR + PR + SD) was 19% (95% CI: 12-28%). The CBRs were 7%, 17%, 21%, and 23% for patients with 1, 2, 3, and ≥ 4 prior treatment lines. Median PFS ranged from 2.6 months (2 lines) to 4.9 months (≥4 lines). The 3-year OS rate was 58% (95% CI: 47-67%). The median OS was 3.4 years (95% CI: 2.9-4.2), ranging from 2.5 years (2 lines) to 4.5 years (≥4 lines). The most common treatment-related adverse event was hypertension; 35 (78%) of 45 were grade 1 or 2. CONCLUSIONS: In heavily pretreated advanced endometrial cancer, bevacizumab was associated with modest clinical efficacy and remains a viable palliative option in this setting.
引用
- Rubinstein MM, Dickinson S, Narayan P, et al. Bevacizumab in advanced endometrial cancer. Gynecol Oncol. 2021. PMID: 33894982. doi:10.1016/j.ygyno.2021.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。